Comparative Pharmacology
Head-to-head clinical analysis: CORTIFOAM versus DEPINAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTIFOAM versus DEPINAR.
CORTIFOAM vs DEPINAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
Depinar is a formulation of estradiol valerate and dihydroxyprogesterone acetophenide, a synthetic progestin. Estradiol valerate is a prodrug of estradiol, which binds to estrogen receptors, activating gene transcription and exerting estrogenic effects. Dihydroxyprogesterone acetophenide is a progestogen that binds to progesterone receptors, inducing endometrial transformation and inhibiting gonadotropin release.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
2.5–5 mg orally once daily, max 10 mg/day
None Documented
None Documented
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
Terminal half-life is 12-15 hours in adults with normal renal function; prolonged to 24-30 hours in moderate renal impairment (CrCl 30-50 mL/min).
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
Primarily renal excretion as unchanged drug (60-70%) and metabolites (20-30%); biliary/fecal elimination accounts for <10%.
Category C
Category C
Corticosteroid
Corticosteroid